Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

• Status: Recruiting
• Trial end date: 2022-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The PIGLETS regimen was devised to replace the conventional SMILE regimen in management of extranodal NK/T cell lymphoma in our institution. It had been three years since the introduction of PIGLETS regimen in treatment of NK malignancies. The response rate is encouraging, with an overall response rate (ORR) of 90% in NK malignancies. Side effects are generally tolerable. The investigator therefore propose the use of PIGLETS on newly diagnosed or relapsed/refractory PTCLs.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Asparaginase; BB 1101; Cisplatin; Dexamethasone; Dexamethasone acetate; Etoposide; Etoposide phosphate; Gemcitabine; Ifosfamide; Isophosphamide mustard

Criteria

Inclusion Criteria:

1. Patients between the age of 18 - 80 years, with confirmed PTCLs

2. Adequate organ functions

3. ECOG performance status of <=2

4. No history of hypersensitivity to any of the components of the PIGLETS regimen

5. Informed consent obtained

Exclusion Criteria:

1. Inadequate organ functions

2. ECOG performance status of >=3